Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress

Journal of Neural Transmission

Volumn 105, Issue 8-9, 1998, Pages 1005-1015

  Loske, C ^a   Neumann, A ^a   Cunningham, A M ^b   Nichol, K ^b   Schinzel, R ^a   Riederer, P ^a   Munch G ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Advanced glycation endproducts; Alzheimer's disease; Cytotoxicity

Indexed keywords

2 OXOGLUTARIC ACID; ACETYLCYSTEINE; AMINOGUANIDINE; AMYLOID BETA PROTEIN; GLYCOSYLATED PROTEIN; LACTATE DEHYDROGENASE; NEUTRAL RED; OVALBUMIN; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FIBROBLAST; GLYCATION; HAMSTER; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; NEUROBLASTOMA CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0031737982     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050108     Document Type: Article

References (25)

1. Beyreuther K, Masters CL (1997) Alzheimers disease - the ins and outs of amyloid-β. Nature 389: 677-678
2. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA (1995) Apoptosis and necrosis - two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide Superoxide in cortical cell cultures. Proc Natl Acad Sci USA 92: 7162-7166
3. Braak H, Braak E, Bohl J, Reintjes R (1996) Age, neurofibrillary changes, Aβ-amyloid and the onset of Alzheimers disease. Neurosci Lett 210: 87-90
4. Bucala R, Vlassara H, Cerami A (1994) Advanced glycosylation endproducts - role in diabetic and non-diabetic vascular disease. Drug Dev Res 32: 77-89
5. Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56: 321-339
6. Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P (1995) Decreased catalase activity but unchanged Superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216-1223
7. Haramaki N, Han D, Handelman GJ, Tritschler HJ, Packer L (1997) Cytosolic and mitochondrial systems for NADH- and NADPH-dependent reduction of alpha-lipoic acid. Free Rad Biol Med 22: 535-542
8. Holstad M, Jansson L, Sandler S (1997) Inhibition of nitric oxide formation by aminoguanidine - an attempt to prevent insulin-dependent diabetes mellitus. Gen Pharmacol 29: 697-700
9. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997) APP (SW) transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965-973
10. 2-microglobulin amyloidosis. Amyloid. Int J Exp Clin Invest 4: 187-211
11. Ledesma MD, Bonay P, Avila J (1995) Tau protein from Alzheimers disease patients is glycated at its tubulin-binding domain. J Neurochem 65: 1658-1664
12. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U (1997) Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 31: 53-64
13. Münch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P (1994) The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm [P-D Sect] 8: 193-208
14. Münch G, Mayer S, Michaelis J, Hipkiss AR, Riederer P, Muller R, Neumann A, Schinzel R, Cunningham AM (1997a) Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Acta [Mol Bas Dis] 1360: 17-29
15. Münch G, Thome J, Foley P, Schinzel R, Riederer P (1997b) Advanced glycation endproducts in ageing and Alzheimers disease. Brain Res Rev 23: 134-143
16. Münch G, Riederer P, Cunningham A, Braak E (1998) Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease. Brain Res (in press)
17. Packer L, Witt EH, Tritschler HJ (1995) Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med 19: 227-250
18. Smith MA, Perry G (1995) Free radical damage, iron, and Alzheimers disease. J Neurol Sei 134: 92-94
19. Smith MA, Monnier VM, Sayre LM, Perry G (1995) Amyloidosis, advanced glycation end products and Alzheimer disease. Neuroreport 6: 1595
20. Smith MA, Harris PLR, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94: 9866-9868
21. Varma SD, Devamanoharan PS, Ali AH (1997) Formation of advanced glycation end (AGE) products in diabetes - prevention by pyruvate and alpha-keto glutarate. Mol Cell Biochem 171: 23-28
22. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91: 4766-4770
23. Van SD, Schmidt AM, Anderson GM, Zhang JH, Brett J, Zou YS, Pinsky D, Stern D (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors binding proteins. J Biol Chem 269: 9889-9897
24. Yan SD, Stern D, Schmidt AM (1997a) Whats the RAGE - the receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest 27: 179-181
25. Yan SD, Zhu HJ, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM (1997b) Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor - a proinflammatory pathway in Alzheimer-disease. Proc Natl Acad Sci USA 94: 5296-5301